

For Healthcare Providers
Prescribing Information
Important Safety Information
Find a Treatment Center
Stay Informed
Contact With an Aplysin Educator

[About ATTR](#)
[How AMVUTTRA Works](#)
Results With AMVUTTRA
[Taking AMVUTTRA](#)
[Resources & Support](#)

ATTR-CM study results

hATTR-PN study results

Proven to help people with ATTR-CM live longer

People lived longer and had fewer heart-related hospital visits

People lived longer with continued treatment

People experienced slower disease progression

Select a **group in the study** to see results for people not taking a stabilizer at the start of the study.

Everyone in the study

A group in the study

Analyses done over 3½ years compared the original AMVUTTRA® (vutrisiran) and placebo groups from the beginning of the study. After 3 years, people taking placebo switched to AMVUTTRA so that everyone still in the study received AMVUTTRA for up to an additional 6 months.

The risk of death was lower over 3½ years with AMVUTTRA.*

36%

Lower Risk
compared to placebo

Survival was estimated in a separate analysis at 3½ years.

This analysis was not included in the original study plan, and other factors could have influenced the results. Talk to your doctor about what this might mean for you.

80%

Survival Rate
for people taking AMVUTTRA at 3½ years
compared to 72% for people taking placebo

*Heart deaths were heart-related. Back to top ↑

Build your personalized discussion guide

This Doctor Discussion Guide can help you prepare for your next appointment and discuss your treatment goals.

If you're the caregiver of someone with ATTR-CM, complete this guide together.

Get started

Or, you can **download** a version to print and fill out.

By submitting this form, I agree to the [Aplysin Privacy Policy](#) and the [Consumer Health Data Broker Policy](#), including the collection of my health-related personal information. I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the [Data Sharing Notification and Consent](#) by Aplysin and Aplysin's partners. I understand that Aplysin will use reasonable technical and organizational measures to protect the information I share when completing this personalized discussion guide.

Up Next

How AMVUTTRA May Help hATTR-PN

→→

Important Safety Information

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about AMVUTTRA, please see the full [Prescribing Information](#).

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

- cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
- polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Privacy Policy | Legal Notice | Contact Us | Site Map

AMVUTTRA, Aplysin Assist, and their associated logos are trademarks of Aplysin Pharmaceuticals, Inc. © 2020 Aplysin Pharmaceuticals, Inc. All rights reserved. This site is intended for US audiences. AMVUTTRA-02405

For Healthcare Providers
Prescribing Information
Important Safety Information
Find a Treatment Center
Site Informed
Connect with an Account Educator

amvuttra
About ATTR
How AMVUTTRA Works
Results With AMVUTTRA
Taking AMVUTTRA
Resources & Support

ATTR-CM study results
NATTR-PN study results

Proven to help people with ATTR-CM live longer

People lived longer and had fewer heart-related hospital visits

People lived longer with continued treatment

People experienced slower disease progression

Select a **group in the study** to see results for people not taking a stabilizer at the start of the study.

Everyone in the study
A group in the study

Analyses done over 3½ years compared the original AMVUTTRA® (vutrisiran) and placebo groups from the beginning of the study. After 3 years, people taking placebo switched to AMVUTTRA so that everyone still in the study received AMVUTTRA for up to an additional 6 months.

The risk of death was lower over 3½ years with AMVUTTRA.*

35%

Lower Risk

compared to placebo

About 60% of people in the study were not taking a stabilizer at the start of the study. The study looked at results for everyone in the study as well as only for this group of people.

Survival was estimated in a separate analysis at 3½ years.

This analysis was not included in the original study plan, and other factors could have influenced the results. Talk to your doctor about what this might mean for you.

76%

Survival Rate

for people taking AMVUTTRA at 3½ years compared to 67% for people taking placebo

*Heart deaths were heart-related.
Back to top

Build your personalized discussion guide

This Doctor Discussion Guide can help you prepare for your next appointment and discuss your treatment goals.

If you're the caregiver of someone with ATTR-CM, complete this guide together.

Get started

Or, you can **download** a version to print and fill out.

By submitting this form, I agree to the [Alnylam Privacy Policy](#) and the [Consumer Health Data Privacy Policy](#), including the collection of my health-related personal information. I am 18 years or older, a U.S. resident, and consent to the processing of my personal data per the terms outlined in the [Data Privacy Notification and Consent](#), by Alnylam and Anjayam's partners. I understand that Anjayam will use reasonable technical and organizational measures to protect the information I share when completing this personalized discussion guide.

Up Next

How AMVUTTRA May Help hATTR-PN

→→

Important Safety Information

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels.

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

- cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce heart-related death, hospital stays and urgent visits.
- polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Privacy Policy
Legal Notice
Contact Us
Site Map

AMVUTTRA, Anjayam Assist, and their associated logos are trademarks of Alnylam Pharmaceuticals, Inc.
© 2024 Alnylam Pharmaceuticals, Inc. All rights reserved. This site is intended for US audiences. AMVUTTRA-01002